reports
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan...
Prospect Capital Announces Annual Meeting Update
Prospect Capital Announces Annual Meeting Update NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its adjourned annual meeting of stockholders (the “Annual Meeting”) on January 8, 2026. The proposals that were considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on September 18, 2025 (the “Proxy”). As of September 17, 2025, there were 465,087,009 shares of the Company's c...
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Health...
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-one investo...
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milesto...
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximat...
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biolog...
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN. BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments fo...
- Jonathan Moreland
WHF WHITEHORSE FINANCE INC.
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
LTC LTC PROPERTIES INC.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
DAKT DAKTRONICS INC.
CUBE CUBESMART
AZO AUTOZONE INC.
ASA ASA
ADC AGREE REALTY CORPORATION
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ULBI NIKE INC. CLASS B
FGBI ULTRALIFE
KOD FIRST GUARANTY BANCSHARES
EML KODIAK SCIENCES
MIDD THE EASTERN COMPANY
PHR THE MIDDLEBY CORPORATION
DHC PHREESIA
ALT DIVERSIFIED HEALTHCARE TRUST
COO ALTIMMUNE INC
AZYO THE COOPER COMPANIES INC.
DLHC AZIYO BIOLOGICS
IMNM DALEIGH HOLDINGS CORP
WRB IMMUNOME
MAIA W.R. BERKLEY CORPORATION
KVUE MAIA BIOTECHNOLOGY INC
GTE KENVUE INC
NBBK GRAN TIERRA ENERGY INC.
SUNS NB BANCORP INC.
ASST SUNRISE REALTY TRUST
MPTI ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under...
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and we...
- Jonathan Moreland
AAON AAON INC.
WHF WHITEHORSE FINANCE INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
AZO AUTOZONE INC.
ASA ASA
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
DIS THE WALT DISNEY COMPANY
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
PHR PHREESIA
DHC DIVERSIFIED HEALTHCARE TRUST
ALT ALTIMMUNE INC
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
DLHC AZIYO BIOLOGICS
AMR DALEIGH HOLDINGS CORP
BMEA ALPHA METALLURGICAL RESOURCES INC
WRB BIOMEA FUSION
NUVL INC.
MAIA W.R. BERKLEY CORPORATION
KVUE NUVALENT INC
GTE MAIA BIOTECHNOLOGY INC
NBBK KENVUE INC
SI GRAN TIERRA ENERGY INC.
ASST NB BANCORP INC.
MPTI SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
Live Ventures Inc: 1 director
A director at Live Ventures Inc sold 3,343 shares at 15.703USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
G-III Apparel Group Ltd: 1 director
A director at G-III Apparel Group Ltd sold 34,693 shares at 31.740USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Jonathan Moreland
ITW ILLINOIS TOOL WORKS INC.
AAON AAON INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
CE CELANESE CORPORATION
APLE APPLE HOSPITALITY REIT INC
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
OXM OXFORD INDUSTRIES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
DIS THE WALT DISNEY COMPANY
NWPP NEW PEOPLES BANKSHARES INC.
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
DHC DIVERSIFIED HEALTHCARE TRUST
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
NOG AZIYO BIOLOGICS
DLHC NORTHERN OIL AND GAS
IMNM DALEIGH HOLDINGS CORP
AMR IMMUNOME
BMEA ALPHA METALLURGICAL RESOURCES INC
LUCY BIOMEA FUSION
KVUE INC.
NBBK INNOVATIVE EYEWEAR INC
SI KENVUE INC
ASST NB BANCORP INC.
SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
CRM SALESFORCE.COM INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
IGR CBRE CLARION GLOBAL REAL ESTAT
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
AZYO AZIYO BIOLOGICS
DLHC DALEIGH HOLDINGS CORP
IMNM IMMUNOME
PROP PRAIRIE OPERATING CO.
MXF THE MEXICO FUND
GF INC.
HYMC THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
Prospect Capital Announces Annual Meeting Update
Prospect Capital Announces Annual Meeting Update NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that it held its annual meeting of stockholders (the “Annual Meeting”) on December 16, 2025. The proposals that were considered at the Annual Meeting are described in detail in the Company’s definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on September 18, 2025 (the “Proxy”). As of September 17, 2025, there were 465,087,009 shares of the Company's common st...
Terns Announces Closing of Public Offering of Common Stock, Including ...
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per sh...
- Wedbush Research
TSLA TESLA INC
NVDA NVIDIA CORPORATION
GOOGL ALPHABET INC. CLASS A
ROKU ROKU INC. CLASS A
MSFT MICROSOFT CORPORATION
DNLI DENALI THERAPEUTICS INC
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
PLTR PALANTIR TECHNOLOGIES
VERA VERA THERAPEUTICS INC
PL PLANET LABS PBC
TYRA TYRA BIOSCIENCES INC
CGON CG ONCOLOGY INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Laura Chico
- Thomas Yip
Terns Announces Pricing of Upsized $650 Million Public Offering
Terns Announces Pricing of Upsized $650 Million Public Offering FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $65...
Vera Therapeutics Announces Pricing of Public Offering of Class A Comm...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share. The gross proceeds to Vera Therapeutics from the offering, before deducting underwriting discounts ...
G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results an...
G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results and Updates Fiscal 2026 Outlook; Initiates First Ever Quarterly Dividend Program Net Income Per Diluted Share of $1.84 and Non-GAAP Net Income Per Diluted Share of $1.90 for the Third Quarter, Both Exceeding GuidanceNet Sales of $988.6 Million for the Third QuarterRaises GAAP and Non-GAAP Net Income Per Diluted Share GuidanceMaintains Strong Cash and Availability PositionIntroduces First Ever Quarterly Dividend of $0.10 Per Share NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NasdaqGS: GIII) (“G-I...
Terns Announces Proposed Public Offering
Terns Announces Proposed Public Offering FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock offered in the publ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.